Comparison of Quality of Life and Injection Site Reactions After Switching from Degarelix 80 mg to 480 mg in Advanced Prostate Cancer: A Prospective Trial
-
Published:2023-03-27
Issue:4
Volume:43
Page:1611-1621
-
ISSN:0250-7005
-
Container-title:Anticancer Research
-
language:en
-
Short-container-title:Anticancer Res
Author:
MIYAJIMA KEIICHIRO,YANAGISAWA TAKAFUMI,SUZUKI HIROTAKA,FUKUOKAYA WATARU,SAKANAKA KEIGO,OBAYASHI KOKI,MIKI JUN,KIMURA TAKAHIRO
Publisher
Anticancer Research USA Inc.
Subject
Cancer Research,Oncology,General Medicine